(JBS) JBS - Overview

Sector: Consumer Defensive | Industry: Packaged Foods | Exchange: NYSE (USA) | Market Cap: 14.221m USD | Total Return: 1.1% in 12m

Processed Meats, Leather, Biodiesel, Hygiene Products
Total Rating 35
Safety 51
Buy Signal -1.41
Packaged Foods
Industry Rotation: +2.8
Market Cap: 14.2B
Avg Turnover: 96.5M
Risk 3d forecast
Volatility40.4%
VaR 5th Pctl7.50%
VaR vs Median12.7%
Reward TTM
Sharpe Ratio0.12
Rel. Str. IBD17.8
Rel. Str. Peer Group50
Character TTM
Beta0.065
Beta Downside-0.523
Hurst Exponent0.567
Drawdowns 3y
Max DD26.82%
CAGR/Max DD0.11
CAGR/Mean DD0.29
EPS (Earnings per Share) EPS (Earnings per Share) of JBS over the last years for every Quarter: "2021-03": 0.2961, "2021-06": 0.6633, "2021-09": 1.1504, "2021-12": 1.0103, "2022-03": 0.8747, "2022-06": 0.7219, "2022-09": 0.6899, "2022-12": 0.4031, "2023-03": -0.0381, "2023-06": -0.0001, "2023-09": 0.1058, "2023-12": 0.0151, "2024-03": 0.1702, "2024-06": 0.1682, "2024-09": 0.3545, "2024-12": 0.1925, "2025-03": 1.32, "2025-06": 1.54, "2025-09": 2.75, "2025-12": 3.07, "2026-03": 0.2047,
EPS CAGR: 275.75%
EPS Trend: 83.4%
Qual. Beats: 0
Revenue Revenue of JBS over the last years for every Quarter: 2021-03: 75251.218, 2021-06: 85626.927, 2021-09: 92625.318, 2021-12: 97192.098, 2022-03: 90866.573, 2022-06: 92191.385, 2022-09: 98928.157, 2022-12: 92865.485, 2023-03: 86683.729, 2023-06: 89382.631, 2023-09: 91409.464, 2023-12: 96340.713, 2024-03: 89147.141, 2024-06: 100606.26, 2024-09: 110497.857, 2024-12: 116700.744, 2025-03: 114127.485, 2025-06: 118973.531, 2025-09: 120550.39, 2025-12: 126273.849, 2026-03: 111465.119,
Rev. CAGR: 13.27%
Rev. Trend: 96.5%
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: JBS JBS

JBS N.V. is a global food processing company specializing in animal proteins, including beef, pork, lamb, and poultry. The firm maintains a diversified portfolio that extends into prepared foods, leather, collagen, and biodiesel, operating under established brands such as Seara, Swift, and Pilgrim’s.

The company utilizes a vertically integrated business model to manage supply chain volatility and capture value across multiple byproduct categories. In the global protein sector, geographic diversification is a critical hedge against regional disease outbreaks and fluctuating feed costs.

Investors can further evaluate these industry dynamics and valuation metrics on ValueRay.

Founded in 1953 and headquartered in the Netherlands, JBS N.V. functions as a major player in the Packaged Foods & Meats sub-industry with a distribution network spanning multiple continents.

Headlines to Watch Out For
  • Global beef cycle dynamics and US cattle supply impact profit margins
  • Feed cost volatility directly influences poultry and pork segment profitability
  • Strategic expansion into value-added prepared foods diversifies revenue streams
  • Regulatory scrutiny and antitrust investigations pose significant compliance risks
  • Currency fluctuations between the Brazilian Real and US Dollar affect earnings reporting
Piotroski VR-10 (Strict) 5.5
Net Income: 9.55b TTM > 0 and > 6% of Revenue
FCF/TA: -0.00 > 0.02 and ΔFCF/TA -5.54 > 1.0
NWC/Revenue: 6.37% < 20% (prev 8.67%; Δ -2.30% < -1%)
CFO/TA 0.05 > 3% & CFO 10.6b > Net Income 9.55b
Net Debt (103b) to EBITDA (33.4b): 3.09 < 3
Current Ratio: 1.50 > 1.5 & < 3
Outstanding Shares: last quarter (1.08b) vs 12m ago -51.40% < -2%
Gross Margin: 12.32% > 18% (prev 0.15%; Δ 1.22k% > 0.5%)
Asset Turnover: 202.1% > 50% (prev 184.5%; Δ 17.52% > 0%)
Interest Coverage Ratio: 2.87 > 6 (EBITDA TTM 33.4b / Interest Expense TTM 7.26b)
Altman Z'' 1.73
A: 0.13 (Total Current Assets 90.8b - Total Current Liabilities 60.4b) / Total Assets 233b
B: 0.00 (Retained Earnings 1.15b / Total Assets 233b)
C: 0.09 (EBIT TTM 20.9b / Avg Total Assets 236b)
D: 0.25 (Book Value of Equity 46.0b / Total Liabilities 186b)
Altman-Z'' = 1.73 = BBB
Beneish M -2.34
DSRI: 1.19 (Receivables 25.9b/20.1b, Revenue 477b/442b)
GMI: 1.22 (GM 12.32% / 15.03%)
AQI: 1.46 (AQ_t 0.35 / AQ_t-1 0.24)
SGI: 1.08 (Revenue 477b / 442b)
TATA: -0.00 (NI 9.55b - CFO 10.6b) / TA 233b)
Beneish M = -2.34 (Cap -4..+1) = BBB
What is the price of JBS shares?

As of May 27, 2026, the stock is trading at USD 12.98 with a total of 9,474,079 shares traded.
Over the past week, the price has changed by +0.93%, over one month by -13.88%, over three months by -15.69% and over the past year by +1.08%.

Is JBS a buy, sell or hold?

JBS has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy JBS.

  • StrongBuy: 0
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the JBS price?
Analysts Target Price 19.6 51.3%
JBS (JBS) - Fundamental Data Overview as of 23 May 2026
Market Cap USD = 14.2b (14.2b USD * 1.0 USD.USD)
P/E Trailing = 8.1975
P/E Forward = 3.8715
P/S = 0.1611
P/B = 1.7274
Revenue TTM = 477b USD
EBIT TTM = 20.9b USD
EBITDA TTM = 33.4b USD
Long Term Debt = 20.5b USD (from longTermDebt, last quarter)
Short Term Debt = 6.21b USD (from shortTermDebt, last quarter)
Debt = 121b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.78b
Net Debt = 103b USD (calculated: Debt 121b - CCE 17.8b)
Enterprise Value = 118b USD (14.2b + Debt 121b - CCE 17.8b)
Interest Coverage Ratio = 2.87 (Ebit TTM 20.9b / Interest Expense TTM 7.26b)
EV/FCF = -1000.0x (Enterprise Value 118b / FCF TTM -64.0m)
FCF Yield = -0.05% (FCF TTM -64.0m / Enterprise Value 118b)
FCF Margin = -0.01% (FCF TTM -64.0m / Revenue TTM 477b)
Net Margin = 2.00% (Net Income TTM 9.55b / Revenue TTM 477b)
Gross Margin = 12.32% ((Revenue TTM 477b - Cost of Revenue TTM 418b) / Revenue TTM)
Gross Margin QoQ = 10.42% (prev 12.08%)
Tobins Q-Ratio = 0.50 (Enterprise Value 118b / Total Assets 233b)
Interest Expense / Debt = 6.00% (Interest Expense 7.26b / Debt 121b)
Taxrate = 21.74% (346.1m / 1.59b)
NOPAT = 16.3b (EBIT 20.9b * (1 - 21.74%))
Current Ratio = 1.50 (Total Current Assets 90.8b / Total Current Liabilities 60.4b)
Debt / Equity = 2.85 (Debt 121b / totalStockholderEquity, last quarter 42.4b)
Debt / EBITDA = 3.09 (Net Debt 103b / EBITDA 33.4b)
 Debt / FCF = -1.62k (out of range, set to none) (Net Debt 103b / FCF TTM -64.0m)
 Total Stockholder Equity = 36.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.04% (Net Income 9.55b / Total Assets 233b)
RoE = 26.35% (Net Income TTM 9.55b / Total Stockholder Equity 36.2b)
RoCE = 36.76% (EBIT 20.9b / Capital Employed (Equity 36.2b + L.T.Debt 20.5b))
RoIC = 9.14% (NOPAT 16.3b / Invested Capital 179b)
WACC = 4.85% (E(14.2b)/V(135b) * Re(6.21%) + D(121b)/V(135b) * Rd(6.00%) * (1-Tc(0.22)))
Discount Rate = 6.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -24.34 | Cagr: -25.25%
 [DCF] Fair Price = unknown (Cash Flow -64.0m)
 EPS Correlation: 83.42 | EPS CAGR: 275.8% | SUE: N/A | # QB: 0
Revenue Correlation: 96.48 | Revenue CAGR: 13.27% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.78 | Chg30d=-24.53% | Revisions=-43% | Analysts=5
EPS next Quarter (2026-09-30): EPS=2.16 | Chg30d=-23.76% | Revisions=-43% | Analysts=5
EPS current Year (2026-12-31): EPS=7.21 | Chg30d=-20.32% | Revisions=-67% | GrowthEPS=-36.6% | GrowthRev=+2.7%
EPS next Year (2027-12-31): EPS=8.27 | Chg30d=-12.81% | Revisions=-33% | GrowthEPS=+14.7% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: -67%